Get notified when LFWD files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: LFWD Lifeward Ltd. 8-K

Lifeward promotes Keith D. Rose, M.D. to Chief Medical Officer

Filed May 19, 2026 · Period ending May 18, 2026 · ~1 min read

Key Changes

  • medium

    Dr. Keith D. Rose appointed Chief Medical Officer effective May 1, 2026, promoted from VP of Medical Affairs after three years with the company. The CMO role is critical for clinical strategy and regulatory interactions at medical device firms.

    Item 5.02 view on EDGAR →
  • low

    Dr. Rose brings experience from Novocure, Biocodex, Ipsen, and Jazz Pharmaceuticals, with medical training in Physical Medicine & Rehabilitation—directly relevant to Lifeward's neuroscience-focused medical devices.

    8-K: Executive Background verify on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.

Partner

Trade LFWD commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · May 25, 2026 · How we verify